Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug

[Reuters] – Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG’s biosimilar form of Neupogen, Amgen’s blockbuster drug used to prevent infections in cancer patients, according . . . → Read More: Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug Similar Articles: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit Stock Update (NASDAQ:AMGN): Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen ovarian cancer drug fails to improve overall survival